Quick Takeaways
- Fairmount Funds Management LLC filed SCHEDULE 13D/A for Dianthus Therapeutics, Inc. /DE/ Common Stock, $0.001 par value (DNTH).
- Disclosed ownership: 9.9%.
- Date of event: 11 Sep 2025.
Quoteable Key Fact
"Fairmount Funds Management LLC disclosed 9.9% ownership in Dianthus Therapeutics, Inc. /DE/ Common Stock, $0.001 par value (DNTH) on 11 Sep 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 9.9% | 4,052,052 | 0 | 4,052,052 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0001802528 |
| Fairmount Healthcare Fund II L.P. | 9.9% | 4,052,052 | 0 | 4,052,052 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0001769651 |
| Fairmount SPV III, LLC | 0% | 0 | 0 | 0 | By: Fairmount Funds Management LLC, its Class A Member, /s/ Peter Harwin | Peter Harwin, Managing Member | |
| Peter Evan Harwin | 9.9% | 4,052,052 | 0 | 4,052,052 | /s/ Peter Harwin | Peter Harwin | 0001663607 |
| Tomas Kiselak | 9.9% | 4,052,052 | 0 | 4,052,052 | /s/ Tomas Kiselak | Tomas Kiselak | 0001830177 |